De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Pieris Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Pieris Pharmaceuticals' is Steve Yoder, benoemd in Dec2014, heeft een ambtstermijn van 9.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.36M, bestaande uit 43% salaris en 57% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.006% van de aandelen van het bedrijf, ter waarde € 499.80. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 6.7 jaar.

Belangrijke informatie

Steve Yoder

Algemeen directeur

US$1.4m

Totale compensatie

Percentage CEO-salaris	43.0%
Dienstverband CEO	9.6yrs
Eigendom CEO	0.006%
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	6.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Steve Yoder's beloning veranderd ten opzichte van Pieris Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$1m	US$585k	-US$25m
Sep 30 2023	n/a	n/a	-US$28m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$41m
Dec 31 2022	US$2m	US$565k	-US$33m
Sep 30 2022	n/a	n/a	-US$35m
Jun 30 2022	n/a	n/a	-US$42m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	US$2m	US$548k	-US$46m
Sep 30 2021	n/a	n/a	-US$51m
Jun 30 2021	n/a	n/a	-US$48m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$2m	US$535k	-US$37m
Sep 30 2020	n/a	n/a	-US$26m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$2m	US$515k	-US$28m
Sep 30 2019	n/a	n/a	-US$36m
Jun 30 2019	n/a	n/a	-US$40m
Mar 31 2019	n/a	n/a	-US$28m
Dec 31 2018	US$3m	US$500k	-US$27m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$18m
Dec 31 2017	US$1m	US$450k	-US$18m

Compensatie versus markt: De totale vergoeding ($USD 1.36M ) Steve } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 509.29K ).

Compensatie versus inkomsten: De vergoeding van Steve is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Steve Yoder (48 yo)

9.6yrs

Tenure

US$1,358,952

Compensatie

Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Yoder	CEO, President & Director	9.6yrs	US$1.36m	0.0057% € 499.8
Thomas Bures	Senior VP	4.8yrs	US$729.04k	0.018% € 1.6k
Shane Olwill	Senior VP & Chief Development Officer	no data	US$705.45k	0.0044% € 386.3
Maria Kelman	Executive Director of Investor Relations	no data	geen gegevens	geen gegevens
Prompong Chaikul	Chief Supply Chain Officer	4.8yrs	geen gegevens	geen gegevens
Florian Witte	VP and Head of Alliance Management & Early Project Leadership	1.5yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PI60 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Yoder	CEO, President & Director	9.6yrs	US$1.36m	0.0057% € 499.8
James Arthur Geraghty	Independent Chairman	7.2yrs	US$94.09k	0.019% € 1.7k
Michael Richman	Independent Director	9.6yrs	US$52.09k	0% € 0
Christopher Kiritsy	Independent Director	7.8yrs	US$72.58k	0.019% € 1.7k
Peter Kiener	Independent Director	5.8yrs	US$65.08k	0% € 0
Matthew Sherman	Independent Director	5.8yrs	US$53.09k	0% € 0
Ann Barbier	Independent Director	6.3yrs	US$52.09k	0% € 0
Maya Said	Independent Director	5yrs	US$52.09k	0% € 0
Ian Adcock	Member of Clinical & Scientific Advisory Board	no data	geen gegevens	geen gegevens
Oliver Eickelberg	Member of Clinical & Scientific Advisory Board	no data	geen gegevens	geen gegevens
Fan Chung	Member of Clinical & Scientific Advisory Board	no data	geen gegevens	geen gegevens
Peter Barnes	Member of Clinical & Scientific Advisory Board	no data	geen gegevens	geen gegevens

6.7yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PI60 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.7 jaar).

Pieris Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Pieris Pharmaceuticals, Inc. Announces Executive Changes

Insufficient new directors

Pieris Pharmaceuticals, Inc. Announces Tim Demuth Steps Down as Senior Vice President and Chief Medical Officer, Effective September 30, 2022

Pieris Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Insufficient new directors

Recent updates

Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. Announce Definitive Merger Agreement

Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.13 loss in 3Q 2022)

Insufficient new directors

Pieris Pharmaceuticals, Inc. Announces Executive Changes

New major risk - Financial position

Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.069 loss in 1Q 2022)

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)

Full year 2022 earnings released: US$0.45 loss per share (vs US$0.71 loss in FY 2021)

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)

Insufficient new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.24 loss in 3Q 2021)

Pieris Pharmaceuticals, Inc. Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

Second quarter 2022 earnings released: US$0.14 loss per share (vs US$0.25 loss in 2Q 2021)

Pieris Pharmaceuticals, Inc. Announces Tim Demuth Steps Down as Senior Vice President and Chief Medical Officer, Effective September 30, 2022

First quarter 2022 earnings released: US$0.069 loss per share (vs US$0.074 loss in 1Q 2021)

Pieris Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2A Trial of PRS-060/AZD1402

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2020)

Insufficient new directors

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.095 loss in 2Q 2020)

Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index

First quarter 2021 earnings released: US$0.074 loss per share (vs US$0.065 loss in 1Q 2020)

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.56 loss in FY 2019)

Pieris Pharmaceuticals, Inc. announced that it expects to receive $10.000002 million in funding from AstraZeneca PLC

Pieris Pharmaceuticals, Inc. announced that it has received $13.008671 million in funding

New 90-day low: €1.99

New 90-day high: €2.47

Third quarter 2020 earnings released: US$0.26 loss per share

Revenue misses expectations

New 90-day low: €1.94

Earnings released

New 90-day low - €2.16

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd